Skip to main content
Top

Luspatercept: A Review in Transfusion-Dependent Anaemia due to Myelodysplastic Syndromes or β-Thalassaemia

Published in:

Abstract

Luspatercept (Reblozyl®), a first-in-class erythroid maturation agent, is approved in several countries worldwide for the treatment of adults with transfusion-dependent anaemia due to myelodysplastic syndromes (MDS), who have failed prior erythropoiesis-stimulating therapy, or β-thalassaemia. In pivotal, placebo-controlled, phase III trials, subcutaneous luspatercept significantly reduced red blood cell (RBC) transfusion requirements in patients with MDS or β-thalassaemia. Luspatercept had a generally manageable tolerability profile in clinical trials. Adverse events of special interest include thromboembolic events, hypertension and bone pain. Thus, luspatercept is an emerging treatment option in adults with transfusion-dependent anaemia due to MDS or β-thalassaemia.
Title
Luspatercept: A Review in Transfusion-Dependent Anaemia due to Myelodysplastic Syndromes or β-Thalassaemia
Authors
Connie Kang
Yahiya Y. Syed
Publication date
01-06-2021
Publisher
Springer International Publishing
Published in
Drugs / Issue 8/2021
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-021-01527-9
This content is only visible if you are logged in and have the appropriate permissions.

Keynote webinar | Spotlight on dry eye disease

DED is highly prevalent yet challenging to diagnose and treat. Join leading experts to explore the latest developments and gain practical guidance on effective management in busy clinical settings. Brought to you by Springer Medicine and Eye.

Prof. Anat Galor
Prof. Sajjad Ahmad
Prof. Harminder Dua
Watch now
Video
Image Credits
Conceptual illustration of dry eye disease/© Science Photo Library / Getty Images